Crossmark

Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment

Crossref DOI link: https://doi.org/10.1186/s40425-019-0653-6

Published Online: 2019-07-12

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hurkmans, Daan P. http://orcid.org/0000-0002-8750-5188
Verhoeven, Jeroen G. H. P.

de Leur, Kitty

Boer, Karin

Joosse, Arjen

Baan, Carla C.

von der Thüsen, Jan H.

van Schaik, Ron H. N.

Mathijssen, Ron H. J.

van der Veldt, Astrid A. M.

Hesselink, Dennis A.
Funding

Funding for this research was provided by:

Dutch Kidney Foundation
License Information

Text and Data Mining valid from 2019-07-12
More Information

Article History

Received: 11 December 2018

Accepted: 26 June 2019

First Online: 12 July 2019

Ethics approval and consent to participate

: Ethics approval of Multomab study (Medical Ethical Board Erasmus MC ref. 16–011), patient signed written informed consent provided before study entry.

: Ethics approval of Multomab study (Medical Ethical Board Erasmus MC ref. 16–011), patient signed written informed consent provided before study entry.

: AV has an advisory role at BMS. Remaining authors declare no potential conflicts of interest.